Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is considered one of the most undervalued NASDAQ stocks to buy now, with a $147 price target set by Piper Sandler. The company is set to release data from its HERIZON-GEA-01 study on zanidatamab as a first-line therapy for advanced gastroesophageal adenocarcinoma in the fourth quarter of 2025.

Piper Sandler recently held a webinar with an oncologist to discuss potential outcomes of Jazz Pharmaceuticals plc’s upcoming clinical trial. If positive, zanidatamab could make a significant impact in the treatment market for gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company known for developing treatments for serious illnesses, including Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos. The company is focused on providing innovative solutions for various health conditions.

While Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. Investors seeking undervalued AI stocks can explore opportunities beyond JAZZ by considering other options in the market.

Read more at Yahoo Finance: Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data